Crocs, a US based footwear manufacturing company has signed an exclusive contract with Surya Pharmaceuticals for marketing their medical footwear in India. Surya Pharmaceuticals and alliance aim to earn revenue to the tune of Rs. 1 billion in India by marketing Crocs medical footwear in the country in the next two years. Crocs Rx Medical has become a household name in the past few years as the company has ventured into developing and manufacturing medical footwear for those having problems of diabetes or arthritis or general foot ailments.
Surya Pharmaceuticals and its alliance aim to sell over 6.5 lac pairs of the footwear in the next 2 years which is a part of their future plan to introduce many international brands in India. The country sees a rising number of percentages of people becoming diabetic each year. According to figures the diabetic population in increasing each year in India at a rate of 10-15% per year. With an ever increasing diabetic population in the country, achieving a sales target of Rs. 1 billion in 2 years does not look impossible at all to the company.
